Natera Inc. Common Stock vs Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) trades at $8.59 (market cap $9.09B). The key difference: Natera Inc. Common Stock is far larger — about 6.3× Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares)'s market cap, and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) pays a 3.84% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) for 0 Days on average.
| NTRA | YMM | |
|---|---|---|
Market Cap | $57.03B | $9.09B |
Volume | 1,131,157 | 10,124,674 |
Sector | Health | Technology |
52-Week High | $425.64 | $13.30 |
52-Week Low | $179.42 | $7.54 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $56.18B | $5.57B |
Dividend Yield | — | 3.84% |
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →Full Truck Alliance Co. Ltd. operates a digital freight-matching platform in China, connecting shippers with truckers for cargo transport across varying distances and load types.
Read more on YMM →